COUMARIN DERIVATIVE TREATMENT: AN OBESERVATIONAL PROSPECTIVE STUDY TO ASSESS INCIDENCE OF ELEVATED INR, ITS ASSOCIATED RISK FACTORS AND THE PATIENT ADHERENCE
The Coumarin derivatives anticoagulant are narrow therapeutic drugs, used globally for the prevention of thromboembolic events. Coumarin derivatives are associated with a risk of bleeding that may restrict their use. Bleeding is the serious complication for the use of oral anticoagulation (Coumarin derivative) in the prevention and treatment of thromoboembolic complications. The purpose of this study is to determine the Incidence of elevated International Normalised Ratio (INR), its associated Risk factors and the Patient Adherence in Coumarin derivative treatment. The risk of bleeding is closely correlated with anticoagulation severity, among others. The key explanation for the risk of bleeding is the elevated INR. The International Normalised Ratio (INR) is a laboratory calculation of how long it takes to clot blood. It is used to assess the effects on the clotting function of oral anticoagulants (coumarin derivatives). The risk of severe haemorrhage (bleeding) is increased by INR values over 5 and INR less than 2 increases the risk of thromboembolism. Different risk factors, including drug interactions such as antibiotics, NSAIDS, food interactions, and other patient-specific risk factors, which change the stability of the level. To avoid bleeding and thrombotic events, the dosage of acenocoumarol and warfarin should be titrated according to INR stability.